Cyclo Therapeutics Inc. (CYTH)
NASDAQ: CYTH
· Real-Time Price · USD
0.72
-0.00 (-0.08%)
At close: Mar 25, 2025, 3:59 PM
Cyclo Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 233.77K | 123.1K | 202.45K | 311.4K | 495.48K | 117.12K | 152.41K | 186.8K | 452.17K | 541.89K | 194.9K | 585.12K | 403.92K | 238.59K | 358.13K |
Cost of Revenue | 16.8K | 931.13K | 836.48K | 876.55K | 38.77K | 19.91K | 10.2K | 15.77K | 33.03K | 73.67K | 16.46K | 68.66K | 22.67K | 30.16K | 34.6K |
Gross Profit | 216.97K | -808.02K | -634.03K | -565.15K | 456.71K | 97.21K | 142.22K | 171.04K | 419.13K | 468.22K | 178.44K | 516.46K | 381.25K | 208.43K | 323.54K |
Operating Income | -8.29M | -5.64M | -5.11M | -5.64M | -4.77M | -4.63M | -5.01M | -4.97M | -4.25M | -3.46M | -2.93M | -2.79M | -3.86M | -3.6M | -4.04M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | 47.00 | 2.48K | 1.62K | 4.03K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -8.83M | -5.98M | -4.34M | -5.64M | -4.77M | -4.64M | -5.01M | -4.98M | -4.25M | -3.45M | -2.77M | -2.79M | -3.86M | -3.6M | -4.04M |
Net Income | -8.83M | -5.98M | -4.34M | -5.64M | -4.77M | -4.64M | -5.01M | -4.81M | -4.25M | -3.45M | 162.86B | -2.79M | -3.86M | -3.6M | -4.04M |
Selling & General & Admin | 2.37M | 1.41M | 1.56M | 1.4M | 1.53M | 1.28M | 1.75M | 1.95M | 1.8M | 2.04M | 2.02M | 1.86M | 2.4M | 1.16M | 1.1M |
Research & Development | 5.49M | 3.49M | 2.85M | 4.14M | 3.47M | 3.17M | 3.4M | 3.18M | 2.86M | 1.87M | 1.08M | 1.41M | 1.84M | 2.64M | 3.26M |
Other Expenses | 646.26K | -79.03K | 540.43K | -2.31M | 1.16M | 1.15M | 6.07K | 5.71K | 7.31K | 8.42K | 9.06K | 9.18K | 6.63K | 6.51K | 5.22K |
Operating Expenses | 8.5M | 4.83M | 4.48M | 5.08M | 5.22M | 4.73M | 5.15M | 5.14M | 4.67M | 3.92M | 3.11M | 3.29M | 4.24M | 3.81M | 4.36M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 184.97K | n/a | n/a | 162.87B | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 441.00 | 501.00 | 373.00 | 1.38K | 1.3K | 403.00 | 819.00 | 1.24K | 2.2K | 5.1K | 4.52K | 13.18K | 2.36K | 1.28K | 1.51K |
Cost & Expenses | 8.52M | 5.76M | 5.31M | 5.95M | 5.26M | 4.75M | 5.16M | 5.16M | 4.7M | 4M | 3.13M | 3.36M | 4.26M | 3.84M | 4.4M |
Income Tax Expense | n/a | n/a | 3.00 | n/a | 3.89K | 3.51K | -94 | -169.38K | -1.62K | -4.03K | -162.87B | 21K | 1.24K | -3.05K | -661 |
Shares Outstanding (Basic) | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M |
Shares Outstanding (Diluted) | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M |
EPS (Basic) | -0.31 | -0.21 | -0.15 | -0.23 | -0.29 | -0.33 | -0.46 | -0.57 | -0.5 | -0.41 | 19.36K | -0.43 | -0.6 | -0.56 | -0.76 |
EPS (Diluted) | -0.31 | -0.21 | -0.15 | -0.23 | -0.29 | -0.33 | -0.46 | -0.57 | -0.5 | -0.41 | 19.36K | -0.43 | -0.6 | -0.56 | -0.76 |
EBITDA | -8.29M | -5.64M | -5.11M | -5.64M | -4.76M | -4.63M | -5M | -4.98M | -4.24M | -3.45M | -2.93M | -2.79M | -3.85M | -3.6M | -4.03M |
EBIT | -8.29M | -5.64M | -5.11M | -5.64M | -4.77M | -4.63M | -5.01M | -4.97M | -4.25M | -3.46M | -2.93M | -2.77M | -3.86M | -3.6M | -4.04M |
Depreciation & Amortization | 2.18K | 2.18K | 2.18K | 4.82K | 4.82K | 4.82K | 4.82K | 4.87K | 5.13K | 4.74K | 4.74K | 4.21K | 4.21K | 4.86K | 3.55K |